Physician

Erin Megan Pettijohn, M.D.

According to 2025 Medicare claims, Erin Pettijohn, M.D. (NPI: 1003101429) practices hematology/oncology in the Muskegon-Norton Shores, MI market, with the plurality of this provider's patient population coming from Muskegon, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 49444-9739. Pettijohn is affiliated with the Trinity Health Integrated Care (ACO ID: A3454) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Pettijohn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 493 traditional Medicare patients, billed 112,411 HCPCS/CPT codes, and received $1,775,394 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,476 prescription claims across 359 beneficiaries totaling $18,536,719 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 25 claims. Open Payments data shows 148 records totaling $143,764. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $597,488 to $1,775,394. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,370 to $18,536,719. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	234	29,558	$597,488
2018	514	77,715	$1,335,194
2019	559	96,491	$1,646,096
2020	573	79,564	$1,536,199
2021	505	86,312	$1,954,669
2022	459	77,859	$1,704,307
2023	488	126,837	$2,074,985
2024	493	112,411	$1,775,394

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	19	21	$1,370
2016	14	45	$63,978
2017	75	215	$489,819
2018	203	1,167	$2,427,448
2019	220	1,788	$5,275,018
2020	259	2,592	$8,183,148
2021	302	2,801	$11,773,885
2022	318	3,250	$15,242,189
2023	335	3,242	$13,532,714
2024	359	3,476	$18,536,719

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	29	$1,698
2022	N/R	25	$1,208
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	214	428	$83
80053	Blood test, comprehensive group of blood chemicals	224	675	$10
36415	Insertion of needle into vein for collection of blood sample	225	943	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	226	942	$8
83615	Lactate dehydrogenase (enzyme) level	161	297	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	274	7,651	$4,586,440
Imbruvica	Ibrutinib	183	5,154	$2,799,777
Lenalidomide	Lenalidomide	161	4,508	$2,236,167
Pomalyst	Pomalidomide	93	2,604	$2,076,784
Venclexta	Venetoclax	114	3,327	$1,235,821

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	118	$2,275	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	30	$141,490	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Erin Megan Pettijohn, M.D.?

Tedicare shows public-source Medicare data for Erin Megan Pettijohn, M.D. (NPI 1003101429), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Erin Megan Pettijohn, M.D. have ACO affiliation data?

Erin Megan Pettijohn, M.D. is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Erin Megan Pettijohn, M.D.?

Erin Megan Pettijohn, M.D. is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Erin Megan Pettijohn, M.D. have Open Payments data?

Erin Megan Pettijohn, M.D. has 148 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.